18 results on '"Tonomura, A."'
Search Results
2. Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers.
- Author
-
Moscoso, Isabel, Rodríguez-Mañero, Moisés, Cebro-Márquez, María, Vilar-Sánchez, Marta E., Serrano-Cruz, Valentina, Vidal-Abeijón, Iria, Martínez-Monzonís, María Amparo, Mazón-Ramos, Pilar, Pedreira, Milagros, González-Juanatey, José Ramón, and Lage, Ricardo
- Subjects
GLOBAL longitudinal strain ,NON-coding RNA ,GENE expression ,HEART injuries ,PATHOLOGICAL physiology - Abstract
Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased morbidity and mortality if not addressed. Early detection of CDTX is essential, and while echocardiographic measures like global longitudinal strain offer promise in identifying early myocardial dysfunction, the search for reliable biomarkers continues. MicroRNAs (miRNAs) are emerging as important non-coding RNA molecules that regulate gene expression post-transcriptionally, influencing key biological processes such as the cell cycle, apoptosis, and stress responses. In cardiovascular diseases, miRNAs have demonstrated potential as biomarkers due to their stability in circulation and specific expression patterns that reflect pathological changes. Certain miRNAs have been linked to CDTX and hold promise for early detection, prognosis, and therapeutic targeting. These miRNAs not only assist in identifying early cardiac injury, but also offer opportunities for personalized interventions by modulating their expression to influence disease progression. As research advances, integrating miRNA profiling with traditional diagnostic methods could enhance the management of CDTX in cancer patients, paving the way for improved patient outcomes and more tailored therapeutic strategies. Further clinical studies are essential to validate the clinical utility of miRNAs in managing CDTX. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Proteomic Profiling of Tears in Blau Syndrome Patients in Identification of Potential Disease Biomarkers.
- Author
-
Galozzi, Paola, Bindoli, Sara, Baggio, Chiara, Battisti, Ilaria, Leonardi, Andrea, Basso, Daniela, Arrigoni, Giorgio, and Sfriso, Paolo
- Subjects
PROTEIN binding ,PROTEIN expression ,BIOMARKERS ,AUTOINFLAMMATORY diseases ,MASS spectrometry - Abstract
Blau syndrome (BS) is a rare autoinflammatory granulomatosis characterized by granulomatous arthritis, uveitis, and dermatitis. Ocular complications are particularly severe in BS, significantly contributing to morbidity. This study aims to identify potential biomarkers for BS ocular degeneration through proteomic profiling of tear samples from affected patients. Seven subjects from the same family, including four carriers of the BS-associated NOD2 mutation (p.E383K), were recruited alongside healthy controls. Tear samples were collected using Schirmer strips and analyzed via mass spectrometry. A total of 387 proteins were identified, with significant differences in protein expression between BS patients, healthy familial subjects, and healthy controls. Key findings include the overexpression of alpha-2-macroglobulin (A2M) and immunoglobulin heavy constant gamma 4 (IGHG4) in BS patients. Bioinformatic analysis revealed that differentially expressed proteins are involved in acute-phase response, extracellular exosome formation, and protein binding. Notably, neutrophils' azurophilic granule components, as azurocidin (AZU1), myeloperoxidases (MPO), and defensins (DEFA3), were highly expressed in the most severely affected subject, suggesting a potential role of neutrophils in BS ocular severity. These proteins might be promising biomarkers for ocular involvement in BS, facilitating early detection and tailored treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Calcific coronary lesions: management, challenges, and a comprehensive review.
- Author
-
Golub, Ilana S., Misic, Angela, Schroeder, Lucia P., Aldana-Bitar, Jairo, Krishnan, Srikanth, Kianoush, Sina, Benzing, Travis, Ichikawa, Keishi, and Budoff, Matthew J.
- Subjects
CORONARY artery calcification ,BIOMARKERS ,INTRAVASCULAR ultrasonography ,PERCUTANEOUS coronary intervention ,OPTICAL coherence tomography - Abstract
As the prevalence of coronary artery disease continues to increase worldwide, understanding the nuances of complex calcific coronary lesions becomes paramount. Coronary artery calcium (CAC) is a well-established, widely available, and highly specific marker of subclinical and advanced atherosclerosis. It remains a vital adjudicator of atherosclerotic cardiovascular disease (ASCVD) and facilitates the up- or down-stratifying of asymptomatic, intermediate risk patients. Notably, the high prevalence of CAC in coronary heart disease (CHD) patients makes the percutaneous treatment of heavily calcified coronary lesions particularly challenging. These cases have a higher risk of immediate complications, late failures due to stent underexpansion or malapposition, and poor clinical outcomes. In this setting, understanding lesion pathophysiology and characterizing calcium deposition with multimodal imaging are crucial steps to improve the successful treatment of these lesions. Therefore, this review explores CAC in the context of complicated and severely calcified lesions. We seek to ameliorate clinical uncertainties and synthesize growing amounts of research to help encourage a homogenous approach to complex calcific coronary lesions. To that end, this comprehensive review paper will first cover epidemiology, pathophysiology, and the types of calcific lesions. Next, we will review acute and long-term complications, as well as lesion preparation and intervention. Last, this review will explore the role of imaging and the contemporary management of severely calcified lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. A Strategy for Allowing Earlier Diagnosis and Rigorous Evaluation of BACE1 Inhibitors in Preclinical Alzheimer's Disease.
- Author
-
Ohno, Masuo
- Subjects
ALZHEIMER'S disease ,EARLY diagnosis ,MEMORY disorders ,MEMORY trace (Psychology) ,MEMORY testing ,CLINICAL trials ,EXPLICIT memory - Abstract
Given continued failure of BACE1 inhibitor programs at symptomatic and prodromal stages of Alzheimer's disease (AD), clinical trials need to target the earlier preclinical stage. However, trial design is complex in this population with negative diagnosis of classical hippocampal amnesia on standard memory tests. Besides recent advances in brain imaging, electroencephalogram, and fluid-based biomarkers, new cognitive markers should be established for earlier diagnosis that can optimize recruitment to BACE1 inhibitor trials in presymptomatic AD. Notably, accelerated long-term forgetting (ALF) is emerging as a sensitive cognitive measure that can discriminate between asymptomatic individuals with high risks for developing AD and healthy controls. ALF is a form of declarative memory impairment characterized by increased forgetting rates over longer delays (days to months) despite normal storage within the standard delays of testing (20–60 min). Therefore, ALF may represent a harbinger of preclinical dementia and the impairment of systems memory consolidation, during which memory traces temporarily stored in the hippocampus become gradually integrated into cortical networks. This review provides an overview of the utility of ALF in a rational design of next-generation BACE1 inhibitor trials in preclinical AD. I explore potential mechanisms underlying ALF and relevant early-stage biomarkers useful for BACE1 inhibitor evaluation, including synaptic protein alterations, astrocytic dysregulation and neuron hyperactivity in the hippocampal-cortical network. Furthermore, given the physiological role of the isoform BACE2 as an AD-suppressor gene, I also discuss the possible association between the poor selectivity of BACE1 inhibitors and their side effects (e.g., cognitive worsening) in prior clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.
- Author
-
Aupperle-Lellbach, Heike, Kehl, Alexandra, de Brot, Simone, and van der Weyden, Louise
- Subjects
VETERINARY medicine ,TUMOR markers ,VETERINARIANS ,INDIVIDUALIZED medicine ,GENETIC translation ,BIOMARKERS ,MOLECULAR pathology - Abstract
Simple Summary: Molecular biomarkers in cancer are measurable genomic alterations that can indicate the risk of developing neoplasia, the presence of neoplastic cells, patient outcome, and/or a likely response to therapy. This review discusses the different uses of molecular biomarkers in the veterinary clinic and how their presence can be determined. In particular, we showcase which genomic alterations are currently used to date as molecular biomarkers in the clinic and for what purposes. We also look at biomarkers that are currently being developed and show promise for clinical use. Finally, we consider the important factors that allow a molecular biomarker to move from the research laboratory to the clinic. This review aims to enable veterinarians to understand the benefits of molecular biomarkers in delivering precision veterinary care to dogs and cats with cancer. Molecular biomarkers are central to personalised medicine for human cancer patients. It is gaining traction as part of standard veterinary clinical practice for dogs and cats with cancer. Molecular biomarkers can be somatic or germline genomic alterations and can be ascertained from tissues or body fluids using various techniques. This review discusses how these genomic alterations can be determined and the findings used in clinical settings as diagnostic, prognostic, predictive, and screening biomarkers. We showcase the somatic and germline genomic alterations currently available to date for testing dogs and cats in a clinical setting, discussing their utility in each biomarker class. We also look at some emerging molecular biomarkers that are promising for clinical use. Finally, we discuss the hurdles that need to be overcome in going 'bench to bedside', i.e., the translation from discovery of genomic alterations to adoption by veterinary clinicians. As we understand more of the genomics underlying canine and feline tumours, molecular biomarkers will undoubtedly become a mainstay in delivering precision veterinary care to dogs and cats with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
- Author
-
Kido-Nakahara, Makiko, Onozuka, Daisuke, Izuhara, Kenji, Saeki, Hidehisa, Nunomura, Satoshi, Takenaka, Motoi, Matsumoto, Mai, Kataoka, Yoko, Fujimoto, Rai, Kaneko, Sakae, Morita, Eishin, Tanaka, Akio, Saito, Ryo, Okano, Tatsuro, Miyagaki, Tomomitsu, Aoki, Natsuko, Nakajima, Kimiko, Ichiyama, Susumu, Tonomura, Kyoko, and Nakagawa, Yukinobu
- Subjects
- *
BLEPHARITIS , *CONJUNCTIVITIS , *BIOMARKERS - Published
- 2024
- Full Text
- View/download PDF
8. Predictive markers for antiinflammatory treatment response in thyroid eye disease.
- Author
-
Haiyang Zhang, Jingyuan Fan, Jialu Qu, Qinghe Han, Huifang Zhou, and Xuefei Song
- Subjects
THYROID eye disease ,BIOMARKERS ,TREATMENT effectiveness - Abstract
Anti-inflammatory treatment is the primary and vital therapeutic approach for active, moderate-to-severe thyroid eye disease (TED). Accurate pretreatment prediction of treatment response is of paramount importance for the prognosis of patients. However, relying solely on the clinical activity score asa determinant of activity has led to unsatisfactory treatment outcomes. In recent years, significant advancements have been made in identifying predictive markers for anti-inflammatory treatment response in TED, clinical markers, body fluid biomarkers and imaging biomarkers. Several clinical studies have developed prediction models based on these markers. However, there is still a lack of comprehensive elucidation or comparison between the different markers. Therefore, this review aims to provide a detailed analysis of the definition, characteristics, and application of predictive markers for anti-inflammatory treatment response in TED. Through detailed literature search, 26 articles applying anti-inflammatory treatment effect prediction with a total of 1948 TED patients were used for analysis and discussion. By gaining a better understanding of the current research on predictive markers, we can accelerate and guide the exploration of treatment prediction strategies, leading us towards an era of precise therapy for TED. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis.
- Author
-
Bazewicz, Magdalena, Heissigerova, Jarmila, Pavesio, Carlos, Willermain, François, and Skrzypecki, Janusz
- Subjects
SARCOIDOSIS ,SYMPTOMS ,COMPUTED tomography ,POSITRON emission tomography computed tomography ,AGE groups ,GENETIC testing - Abstract
Sarcoidosis-associated uveitis, is the predominant ocular sarcoidosis presentation, which affects both adults and children. For adults, international ocular sarcoidosis criteria (IWOS) and sarcoidosis-associated uveitis criteria (SUN) are defined. However, for children they are not yet established internationally. Due to the specificity of pediatric manifestations of sarcoidosis, this task is even more challenging. In children, sarcoidosis is subdivided into Blau syndrome and early-onset sarcoidosis (BS/EOS) affecting younger children (< 5 years) and the one affecting older children with clinical presentation resembling adults. Differential diagnosis, clinical work-up as well as diagnostic criteria should be adapted to each age group. In this article, we review the clinical manifestation of sarcoidosis-associated uveitis in adults and children and the sensitivity and specificity of various ocular sarcoidosis diagnostic modalities, including chest X-ray and CT, FDG PET-CT, gallium-67 scintigraphy, bronchoalveolar lavage fluid, genetic testing for NOD2 mutations and serum biomarkers, such as ACE, lysozyme and IL2R. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Contemporary Biomarkers for Renal Transplantation: A Narrative Overview.
- Author
-
Novacescu, Dorin, Latcu, Silviu Constantin, Bardan, Razvan, Daminescu, Liviu, and Cumpanas, Alin Adrian
- Subjects
KIDNEY transplantation ,SCIENTIFIC literature ,CHRONIC kidney failure ,RENAL tubular transport disorders ,GRAFT rejection ,BIOMARKERS - Abstract
Renal transplantation (RT) is the preferred treatment for end-stage renal disease. However, clinical challenges persist, i.e., early detection of graft dysfunction, timely identification of rejection episodes, personalization of immunosuppressive therapy, and prediction of long-term graft survival. Biomarkers have emerged as valuable tools to address these challenges and revolutionize RT patient care. Our review synthesizes the existing scientific literature to highlight promising biomarkers, their biological characteristics, and their potential roles in enhancing clinical decision-making and patient outcomes. Emerging non-invasive biomarkers seemingly provide valuable insights into the immunopathology of nephron injury and allograft rejection. Moreover, we analyzed biomarkers with intra-nephron specificities, i.e., glomerular vs. tubular (proximal vs. distal), which can localize an injury in different nephron areas. Additionally, this paper provides a comprehensive analysis of the potential clinical applications of biomarkers in the prediction, detection, differential diagnosis and assessment of post-RT non-surgical allograft complications. Lastly, we focus on the pursuit of immune tolerance biomarkers, which aims to reclassify transplant recipients based on immune risk thresholds, guide personalized immunosuppression strategies, and ultimately identify patients for whom immunosuppression may safely be reduced. Further research, validation, standardization, and prospective studies are necessary to fully harness the clinical utility of RT biomarkers and guide the development of targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction.
- Author
-
Tonry, Claire, Russell-Hallinan, Adam, McCune, Claire, Collier, Patrick, Harbinson, Mark, Dixon, Lana, and Watson, Chris J
- Subjects
TUMOR markers ,HEART diseases ,PHYSIOLOGY ,THERAPEUTICS ,CANCER survivors - Abstract
Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially address this need as they are often indicative of cardiac stress before cardiac damage can be detected clinically. A growing understanding of the underlying physiological mechanisms for CTRCD has inspired research efforts to identify novel pathophysiologically relevant biomarkers that may also guide development of cardio-protective therapeutic approaches. The purpose of this review is to evaluate current circulating biomarkers of cardiac stress and their potential role in diagnosis and management of CTRCD. We also discuss some emerging avenues for CTRCD-focused biomarker investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Focus on using nanopore technology for societal health, environmental, and energy challenges.
- Author
-
Tanimoto, Izadora Mayumi Fujinami, Cressiot, Benjamin, Greive, Sandra J., Le Pioufle, Bruno, Bacri, Laurent, and Pelta, Juan
- Abstract
With an increasing global population that is rapidly ageing, our society faces challenges that impact health, environment, and energy demand. With this ageing comes an accumulation of cellular changes that lead to the development of diseases and susceptibility to infections. This impacts not only the health system, but also the global economy. As the population increases, so does the demand for energy and the emission of pollutants, leading to a progressive degradation of our environment. This in turn impacts health through reduced access to arable land, clean water, and breathable air. New monitoring approaches to assist in environmental control and minimize the impact on health are urgently needed, leading to the development of new sensor technologies that are highly sensitive, rapid, and low-cost. Nanopore sensing is a new technology that helps to meet this purpose, with the potential to provide rapid point-of-care medical diagnosis, real-time on-site pollutant monitoring systems to manage environmental health, as well as integrated sensors to increase the efficiency and storage capacity of renewable energy sources. In this review we discuss how the powerful approach of nanopore based single-molecule, or particle, electrical promises to overcome existing and emerging societal challenges, providing new opportunities and tools for personalized medicine, localized environmental monitoring, and improved energy production and storage systems. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity.
- Author
-
Desai, Varsha G., Vijay, Vikrant, Lee, Taewon, Han, Tao, Moland, Carrie L., Phanavanh, Bounleut, Herman, Eugene H., Stine, Kimo, and Fuscoe, James C.
- Subjects
DOXORUBICIN ,CARDIOTOXICITY ,FALSE discovery rate ,MYOCARDIAL injury ,BIOMARKERS ,CARDIAC patients - Abstract
Cardiotoxicity is a serious adverse effect of an anticancer drug, doxorubicin (DOX), which can occur within a year or decades after completion of therapy. The present study was designed to address a knowledge gap concerning a lack of circulating biomarkers capable of predicting the risk of cardiotoxicity induced by DOX. Profiling of 2083 microRNAs (miRNAs) in mouse plasma revealed 81 differentially expressed miRNAs 1 week after 6, 9, 12, 18, or 24 mg/kg total cumulative DOX doses (early‐onset model) or saline (SAL). Among these, the expression of seven miRNAs was altered prior to the onset of myocardial injury at 12 mg/kg and higher cumulative doses. The expression of only miR‐34a‐5p was significantly (false discovery rate [FDR] < 0.1) elevated at all total cumulative doses compared with concurrent SAL‐treated controls and showed a statistically significant dose‐related response. The trend in plasma miR‐34a‐5p expression levels during DOX exposures also correlated with a significant dose‐related increase in cardiac expression of miR‐34a‐5p in these mice. Administration of a cardioprotective drug, dexrazoxane, to mice before DOX treatment, significantly mitigated miR‐34a‐5p expression in both plasma and heart in conjunction with attenuation of cardiac pathology. This association between plasma and heart may suggest miR‐34a‐5p as a potential early circulating marker of early‐onset DOX cardiotoxicity. In addition, higher expression of miR‐34a‐5p (FDR < 0.1) in plasma and heart compared with SAL‐treated controls 24 weeks after 24 mg/kg total cumulative DOX dose, when cardiac function was altered in our recently established delayed‐onset cardiotoxicity model, indicated its potential as an early biomarker of delayed‐onset cardiotoxicity. Traditional technologies or cardiac disease markers have low sensitivity in detecting early signs of subclinical changes in hearts of cancer patients treated with doxorubicin (DOX). The present study identified miRNA‐34a‐5p as a potential early circulating biomarker of DOX cardiotoxicity in mice 1 week after receiving 6, 9, 12, 18, or 24 mg/kg total cumulative doses. Higher expression of miR‐34a‐5p in plasma at 24 weeks after receiving 24 mg/kg total dose suggested its potential as an early biomarker of delayed‐onset cardiotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. The Future of Biomarkers in Veterinary Medicine: Emerging Approaches and Associated Challenges.
- Author
-
Perera, Tharangani R.W, Skerrett-Byrne, David A., Gibb, Zamira, Nixon, Brett, and Swegen, Aleona
- Subjects
VETERINARY medicine ,BIOMARKERS ,TECHNOLOGICAL innovations ,LIPIDOMICS ,METABOLOMICS ,ANIMAL health - Abstract
Simple Summary: In this review we seek to outline the role of new technologies in biomarker discovery, particularly within the veterinary field and with an emphasis on 'omics', as well as to examine why many biomarkers-despite much excitement-have not yet made it to clinical practice. Further we emphasise the critical need for close collaboration between clinicians, researchers and funding bodies and the need to set clear goals for biomarker requirements and realistic application in the clinical setting, ensuring that biomarker type, method of detection and clinical utility are compatible, and adequate funding, time and sample size are available for all phases of development. New biomarkers promise to transform veterinary practice through rapid diagnosis of diseases, effective monitoring of animal health and improved welfare and production efficiency. However, the road from biomarker discovery to translation is not always straightforward. This review focuses on molecular biomarkers under development in the veterinary field, introduces the emerging technological approaches transforming this space and the role of 'omics platforms in novel biomarker discovery. The vast majority of veterinary biomarkers are at preliminary stages of development and not yet ready to be deployed into clinical translation. Hence, we examine the major challenges encountered in the process of biomarker development from discovery, through validation and translation to clinical practice, including the hurdles specific to veterinary practice and to each of the 'omics platforms–transcriptomics, proteomics, lipidomics and metabolomics. Finally, recommendations are made for the planning and execution of biomarker studies with a view to assisting the success of novel biomarkers in reaching their full potential. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Emerging Detection Techniques for Large Vessel Occlusion Stroke: A Scoping Review.
- Author
-
Nicholls, Jennifer K., Ince, Jonathan, Minhas, Jatinder S., and Chung, Emma M. L.
- Subjects
POSTERIOR cerebral artery ,ANTERIOR cerebral artery ,CEREBRAL arteries ,ISCHEMIC stroke ,GREY literature - Abstract
Background: Large vessel occlusion (LVO) is the obstruction of large, proximal cerebral arteries and can account for up to 46% of acute ischaemic strokes (AIS) when both the A2 and P2 segments are included (from the anterior and posterior cerebral arteries). It is of paramount importance that LVO is promptly recognised to provide timely and effective acute stroke management. This review aims to scope recent literature to identify new emerging detection techniques for LVO. As a good comparator throughout this review, the commonly used National Institutes of Health Stroke Scale (NIHSS), at a cut-off of ≥11, has been reported to have a sensitivity of 86% and a specificity of 60% for LVO. Methods: Four electronic databases (Medline via OVID, CINAHL, Scopus, and Web of Science), and grey literature using OpenGrey, were systematically searched for published literature investigating developments in detection methods for LVO, reported from 2015 to 2021. The protocol for the search was published with the Open Science Framework (10.17605/OSF.IO/A98KN). Two independent researchers screened the titles, abstracts, and full texts of the articles, assessing their eligibility for inclusion. Results: The search identified 5,082 articles, in which 2,265 articles were screened to assess their eligibility. Sixty-two studies remained following full-text screening. LVO detection techniques were categorised into 5 groups: stroke scales (n = 30), imaging and physiological methods (n = 15), algorithmic and machine learning approaches (n = 9), physical symptoms (n = 5), and biomarkers (n = 3). Conclusions: This scoping review has explored literature on novel and advancements in pre-existing detection methods for LVO. The results of this review highlight LVO detection techniques, such as stroke scales and biomarkers, with good sensitivity and specificity performance, whilst also showing advancements to support existing LVO confirmatory methods, such as neuroimaging. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Researcher from Nara Medical University Reports on Findings in Acute Respiratory Distress Syndrome (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4 Regulates Pulmonary Vascular Hyperpermeability through Destruction of...).
- Subjects
ADULT respiratory distress syndrome ,RESEARCH personnel ,RESPIRATORY distress syndrome ,MEMBRANE proteins ,RESPIRATORY diseases - Abstract
A recent study conducted by researchers from Nara Medical University in Japan has investigated the molecular mechanisms underlying acute respiratory distress syndrome (ARDS). The researchers focused on a protein called ADAMTS4, which was found to be induced in lung cells during ARDS. Suppression of ADAMTS4 was shown to improve vascular permeability and protect against reductions in certain proteins involved in maintaining the integrity of blood vessels. These findings suggest that ADAMTS4 may serve as a predictive marker and potential therapeutic target for ARDS. [Extracted from the article]
- Published
- 2023
17. Functional Outcome Prediction of Acute Ischemic Stroke Based on the Oral and Gut Microbiota
- Author
-
Liang, Jingru, Ren, Yueran, Zheng, Yifeng, Lin, Xiaofei, Song, Wei, Zhu, Jiajia, Zhang, Xiaomei, Zhou, Hongwei, Wu, Qiheng, He, Yan, and Yin, Jia
- Published
- 2024
- Full Text
- View/download PDF
18. Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study
- Author
-
Fionda, Laura, Leonardi, Luca, Tufano, Laura, Lauletta, Antonio, Morino, Stefania, Merlonghi, Gioia, Costanzo, Rocco, Rossini, Elena, Forcina, Francesca, Marando, Demetrio, Sarzi Amadè, David, Bucci, Elisabetta, Salvetti, Marco, Antonini, Giovanni, and Garibaldi, Matteo
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.